Eli Lilly and Company (LLY) on Tuesday said its tender offer to acquire Adverum Biotechnologies expired on December 8, 2025, with 16.49 million shares about 64 percent of outstanding shares validly tendered.
With all conditions met, Lilly will promptly pay $3.56 per share in cash plus a contingent value right worth up to $8.91 upon milestone achievements.
The companies expect to complete the merger on December 9 under their existing agreement.
LLY is currently trading at $1,002.72 down $5.15 or 0.52 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.